Yahoo Finance

American biotechnology company Biogen (BIIB) expects lower profits in 2025, impacted by a stronger dollar (DX=F, DX-Y.NYB) and competition for its multiple sclerosis (MS) drugs.

Despite this, the company beat fourth quarter expectations — driven by cost-cutting and new product launches, including its Alzheimer's drug.

Watch the video above to hear hosts Brad Smith and Seana Smith discuss Biogen's latest developments.

To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.

This post was written by Josh Lynch